Factory 99% Tegafur Powder CAS 17902-23-7 Chemical Intermediate Tegafur

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A999
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Tegafur
• CAS: 17902-23-7
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Tegafur
Appearance	White Powder
CAS NO.	17902-23-7
Storage	Keep in a cool, dry, dark location

 

Tegafur is a fluoropyrimidine prodrug and a derivative of 5-fluorouracil (5-FU). It acts as a reservoir for 5-FU, being metabolized in the liver by cytochrome P450 enzymes to release the active agent, thereby inhibiting DNA and RNA synthesis in cancer cells.

 

1. Solid Tumor Treatment: Primarily used for gastrointestinal cancers (e.g., gastric, colorectal) and breast cancer, either as monotherapy or in combination regimens (e.g., with leucovorin or cisplatin).
2. Adjuvant Therapy: Employed post-surgery to eliminate residual micro-metastases and reduce recurrence risk.
3. Palliative Care: Administered to manage advanced-stage malignancies, improving survival and quality of life.

1. Antimetabolite Action: Tegafur disrupts DNA replication by inhibiting thymidylate synthase and blocking RNA transcription, leading to apoptosis in S-phase tumor cells.
2. Prodrug Mechanism: Acts as a sustained-release formulation of 5-FU, reducing systemic toxicity while maintaining therapeutic efficacy.
3. Synergistic Potential: Enhances treatment outcomes when combined with other chemotherapeutics or targeted therapies (e.g., bevacizumab) by exploiting different anti-cancer pathways.